Advertisement

Picture Berlin Partner German Biotech Days 2024 in Berlin 650x100px
Document › Details

Boehringer Ingelheim. (10/2/23). "Press Release: Boehringer Ingelheim and Zeiss Join Forces to Early Detect Eye Diseases and Prevent Vision Loss". Ingelheim & Jena.

Organisation Organisation Boehringer Ingelheim (Group)
Product Product  diagnostics (medical/biological)
     


Boehringer Ingelheim and ZEISS Medical Technology announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and prevent vision loss for people with serious eye diseases. The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms, and the development of treatments to detect early and treat retinal diseases before irreversible loss of vision occurs

More than 300 million people worldwide are at risk today of losing their eyesight due to diseases leading to functional loss of the retina.* The number of people suffering from vision loss is expected to rise due to aging populations and widening health inequity gaps. Undiagnosed and untreated retinal diseases can have a profound impact on people’s lives, potentially leading to isolation, loss of independence, depression, and reduced quality of life. Unfortunately, diagnosis often occurs too late to prevent vision loss, and for many conditions, no treatment is available at all.

The new partnership will focus on identifying markers of early stages of retinal diseases by leveraging ZEISS Medical Technology’s cloud-connected devices and AI-assisted analysis of its extensive image data sets. This will provide a basis for clinical studies for development of more personalized and precise treatments of early stages of chronic retinal disease as well as earlier detection and prediction capabilities to preserve vision through new treatment pathways.

“At ZEISS, we have long understood that where collaboration thrives, innovation emerges,“ said Euan S. Thomson, Head of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology. “With our announcement today with Boehringer Ingelheim, we’re building on our strategy to innovate through partnerships in order to make breakthrough discoveries to combat vision loss and improve people’s lives.”

“Our partnership with ZEISS will allow us to develop precision therapies delivering the right treatment for the right patient at the right time to prevent vision loss by intervening before irreversible damage occurs. It is part of our commitment to champion early detection and treatment and will contribute to transforming the lives of people with serious eye disease,” said Ulrike Graefe-Mody, Ph.D., Head of Retinal Health at Boehringer Ingelheim.

As a leading pioneer of science in optics for more than 100 years, ZEISS’s medical expertise and digital leadership is foundational to the ZEISS Medical Ecosystem and its digitally connected workflows. This connected and secure architecture integrates diagnostic and therapeutic devices supported by a cloud-based platform in which data aggregation, automation and AI analytics can be harnessed to drive new discoveries.

Boehringer Ingelheim has a leading understanding of disease biology aiming at a paradigm change in retinal health through early detection and intervention to achieve meaningful improvements for patients. Over the past decade Boehringer Ingelheim has built a diverse pipeline, which focuses on three priority areas to address retinal conditions – the preservation of vascular function, targeting inflammation and neuroprotection.


Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com  


Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,224 employees worldwide, the Group generated revenue of €1,902.8m in fiscal year 2021/22 (to 30 September).


Carl Zeiss Meditec contact for investors:

Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
investors.meditec@zeiss.com

Carl Zeiss Meditec contact for the press:

Frank E. Smith
Head of Global Communications Ophthalmology
Carl Zeiss Meditec Inc.
Phone: +1 925 487 3036
frank.smith@zeiss.com


Boehringer Ingelheim’s Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.


References

*World Health Organization, World Report on Vision, Executive Summary, October 8, 2019, https://www.who.int/publications/i/item/world-report-on-vision

Media Contacts

Harro Ten Wolde
Head of Global Media Relations
E-Mail: harro.ten_wolde@boehringer-ingelheim.com
Phone Number: +49 (6132) 77-181352

   
Record changed: 2024-01-06

Advertisement

Picture Berlin Partner German Biotech Days 2024 in Berlin 650x200px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top